Survey Finds Nearly 50% of Clinical Research Will Adopt Decentralized Trials Within Next Year
VivaLNK has announced the results of a survey of pharma, biotech, and clinical research professionals on their opinions about the current state of remote patient monitoring (RPM). Findings unveil significant growth and advancement of RPM technologies throughout the course of the COVID-19 pandemic.
The survey reveals that nearly half (44%) have already adopted RPM for decentralized clinical trials or have plans to within the next 12 months. The adoption of remote monitoring during trials stems largely from COVID-19, as 65% of respondents noted concerns related to the pandemic as their primary driver for using RPM technology.
For more of the survey’s findings, click here.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
